Releasing Bound Or Adhered Cell Using Protease Patents (Class 435/380)
-
Patent number: 11788051Abstract: A cell separation device configured for separating cells from microcarriers or spheroids in a liquid is provided. The cell separation device includes a vessel comprising a first port, a second port, and a cavity; and a porous mesh disposed within the cavity to divide the cavity into a first compartment and a second compartment, wherein the first port is in communication with the first compartment of the cavity, the first port located to a first side of the porous mesh, wherein the second port is in communication with the second compartment of the cavity, the second port located to a second side of the porous mesh, and wherein the porous mesh is positioned within the cavity to have a substantially vertical orientation or an inclined orientation with respect to a flow of liquid through the porous mesh.Type: GrantFiled: December 13, 2016Date of Patent: October 17, 2023Assignee: CORNING INCORPORATEDInventors: Gregory Roger Martin, Allison Jean Tanner
-
Publication number: 20150147808Abstract: The present invention relates to the use of warmers, or autonomous heat packs, for heating and maintaining a solution on at a suitable temperature, for the period of time required to accomplish a chemical, biochemical or biological reaction, in particular in molecular biology or cell biology applications. Biology kits containing warmers are also part of this invention.Type: ApplicationFiled: April 16, 2013Publication date: May 28, 2015Applicant: Laboratoires GenevrierInventors: Dominique Vacher, Jean-Noel Gouze
-
Patent number: 8993266Abstract: The present disclosure provides for proprotein and activatable proprotein compositions. A proprotein contains a functional protein (i.e. a full length protein or functional fragment thereof) which is coupled to a peptide mask that inhibits the binding of the functional protein to its target or binding partner. An activatable proprotein contains a functional protein coupled to a peptide mask, and further coupled to an activatable linker, wherein in an non-activated state, the peptide mask inhibits binding of the functional protein to its target or binding partner and in an activated state the peptide mask does not inhibit binding of the functional protein to its target or binding partner. Proproteins can provide for reduced toxicity and adverse side effects that could otherwise result from binding of a functional protein at non-treatment sites if it were not inhibited from binding its binding partner. Proproteins can further provide improved biodistribution characteristics.Type: GrantFiled: December 20, 2012Date of Patent: March 31, 2015Assignee: CytomX Therapeutics, Inc.Inventors: Nancy E. Stagliano, James W. West, Kathryn Kamath, Paul H. Bessette, Jason Sagert
-
Patent number: 8815585Abstract: The invention concerns methods for automated culture of embryonic stem cells (ESCs) such as human ESCs. In some aspects, methods of the invention employ optimized culture media and limited proteolytic treatment of cells to separate cell clusters for expansion. Automated systems for passage and expansion of ESCs are also provided.Type: GrantFiled: June 30, 2008Date of Patent: August 26, 2014Assignee: Cellular Dynamics International, Inc.Inventors: Nathaniel Beardsley, Veit Bergendahl, Megan Fitzgerald, Christine Daigh
-
Patent number: 8765471Abstract: The use of a neutral protease (NP) together with a collagenase consists in that a neutral protease which is not contained in a collagenase enzyme preparation and which is not produced by a recombinant production is mixed before the beginning of a tissue dissociation with a collagenase or a collagenase enzyme preparation with an individual dosage of the quantitative proportions of neutral protease and collagenase for improving the isolation results with respect to yield, viability and integrity of the cells.Type: GrantFiled: April 15, 2013Date of Patent: July 1, 2014Assignee: Nordmark Arzneimittel GmbH & Co. KGInventors: Manfred Kurfuerst, Christian Raemsch, Nicole Raemsch-Guenther, Olaf Friedrich, Silke Huettler, Daniel Brandhorst, Thierry Berney, Pascal Bucher, Heide Brandhorst
-
Publication number: 20140178995Abstract: This invention is directed to methods of directly reseeding harvested adherent cells grown in a hollow fiber bioreactor. Also disclosed is a novel harvest media for use in directly reseeding adherent cells into a hollow fiber bioreactor.Type: ApplicationFiled: February 27, 2014Publication date: June 26, 2014Applicant: Terumo BCT, Inc.Inventors: Glen Delbert ANTWILER, David A. WINDMILLER, Monique GIVENS
-
Patent number: 8728819Abstract: The present invention relates to novel methods of growing at least 100 million minimally-passaged fibroblasts from a small biopsy specimen. The invention includes methods wherein a small biopsy specimen is seeded directly into a large tissue culture flask, and passaged no more than three times.Type: GrantFiled: August 29, 2007Date of Patent: May 20, 2014Assignee: Fibrocell Technologies, Inc.Inventors: John Maslowski, Myrna F. Thomas, Marie A. Lindner
-
Patent number: 8691565Abstract: This invention is directed to methods of directly reseeding harvested adherent cells grown in a hollow fiber bioreactor. Also disclosed is a novel harvest media for use in directly reseeding adherent cells into a hollow fiber bioreactor.Type: GrantFiled: May 4, 2011Date of Patent: April 8, 2014Assignee: Terumo BCT, Inc.Inventors: Glen Delbert Antwiler, David A. Windmiller, Monique Givens
-
Publication number: 20140057281Abstract: The present invention provides a method of producing a cell sheet including the following steps (1) seeding and culturing retinal pigment epithelial cells on a collagen gel to form a cell sheet composed of the retinal pigment epithelial cells, and (2) degrading the collagen gel with collagenase to detach the cell sheet composed of the retinal pigment epithelial cells, and the like.Type: ApplicationFiled: February 24, 2012Publication date: February 27, 2014Applicant: RIKENInventors: Masayo Takahashi, Satoshi Okamoto, Hiroyuki Kamao
-
Publication number: 20130236970Abstract: The present invention relates to a method for cell expansion. More closely, it relates to a method for expansion of cells, such as mesenchymal stem cells, on microcarriers in a plastic bag bioreactor. The invention enables expansion to therapeutic amounts of stem cells. The method comprises the following steps: a) addition of cells in cell culture medium and microcarriers to a plastic bag container; b) allowing the cells to adhere to the microcarriers while the container is kept substantially still; c) addition of further cell culture medium once the cells have adhered; d) culturing the cells under gentle and constant agitation; e) increase the surface area for continued culturing; and f) final harvesting of cells by an active detachment and separation step.Type: ApplicationFiled: April 19, 2013Publication date: September 12, 2013Applicant: GE HEALTHCARE BIO-SCIENCES ABInventors: CECILIA ANNEREN, CHRISTIAN KAISERMAYER, MATS LUNDGREN, JOHANNA TSCHOP, THERESE LUNDSTROM, ANN-CHRISTIN MAGNUSSON, GERALD BLUEML
-
Patent number: 8481311Abstract: Human progenitor cells are extracted from perivascular tissue of human umbilical cord. The progenitor cell population proliferates rapidly, and harbors osteogenic progenitor cells and MHC?/? progenitor cells, and is useful to grow and repair human tissues including bone.Type: GrantFiled: June 11, 2009Date of Patent: July 9, 2013Assignee: Tissue Regeneration Therapeutics Inc.Inventors: John E. Davies, Dolores Baksh, Rahul Sarugaser, Morris Hosseini, Antony D. S. Lickorish
-
Patent number: 8460860Abstract: A bone implant comprising cancellous bone that is essentially free of blood cells, and which has been treated with at least a loosening agent, such as collagenase and/or a digestive enzyme, for a time and at a concentration to loosen the osteogenic cells in the cancellous bone matrix. The osteogenic cells in the matrix are viable cells. The treatment of the cancellous bone with at least one loosening agent enables the osteogenic cells to be more available for carrying our their osteogenic function and to provide for an increased rate of bone formation.Type: GrantFiled: May 2, 2007Date of Patent: June 11, 2013Assignee: NuVasive, Inc.Inventors: Michelle LeRoux Williams, Charles Randal Mills, Rodney Monroy
-
Patent number: 8440445Abstract: The use of a neutral protease (NP) together with a collagenase consists in that a neutral protease which is not contained in a collagenase enzyme preparation and which is not produced by a recombinant production ia mixed before the beginning of a tissue dissociation with a collagenase or a collagenase enzyme preparation with an individual dosage of the quantitative proportions of neutral protease and collagenase for improving the isolation results with respect to yield, viability and integrity of the cells.Type: GrantFiled: June 16, 2004Date of Patent: May 14, 2013Assignee: Nordmark Arzneimittel GmbH & Co. KGInventors: Manfred Kurfürst, Christian Raemsch, Nicole Raemsch-Guenther, Olaf Friedrich, Silke Huettler, Daniel Brandhorst, Thierry Berney, Pascal Bucher, Heide Brandhorst
-
Patent number: 8394631Abstract: The present invention provides a fluid exchange cell culture technique and tissue repair cells (TRCs) made by these methods, as well as methods using these cells. The method includes a new wash step which increases the tissue repair properties of the TRCs of the invention. This wash step allows for the production of TRC populations with greater tissue repair and anti-inflammatory capabilities. Embodiments of the present invention include a post-culture process for cultured cells that preferably includes the steps of: a wash process for removing unwanted residual culture components, a volume reduction process, and a harvesting process to remove cultured cells. Preferably, all these steps are performed within a aseptically closed cell culture chamber by implementing a separation method that minimizes mechanical disruption of the cells and is simple to automate. The harvested cells may then be concentrated to a final volume for the intended use.Type: GrantFiled: December 7, 2010Date of Patent: March 12, 2013Assignee: Aastrom Biosciences, Inc.Inventors: Brian Hampson, Kristin Goltry, Douglas M. Smith, Jonathan A. Rowley, Naia Venturi
-
Publication number: 20130055417Abstract: The invention provides tissue culture system for primary cells (e.g. normal mammalian primary epithelial progenitors). This system includes: a) a serum-free, chemically defined cell culture media; and, b) methods for isolation and in vitro long-term propagation of primary cells (e.g. primary epithelial cells). Primary cells so isolated and cultured can be kept undifferentiated and proliferate for many weeks (>15 weeks) or population doubling (>35 PD) without senescence, or any detectable genetic alterations. Upon changing media/culture conditions, these cells can be induced to differentiate. The invention also provides methods to transform normal primary cells so cultured into “cancer stem cells.” The genetically defined cancer stem cell tumor model mimics the behavior of the disease closely, e.g., the cells are invasive, hormone responsive and metastatic when injected into mice. The tumor cells express genes that are specific to cancer stem cells identified in patient samples.Type: ApplicationFiled: July 23, 2012Publication date: February 28, 2013Applicants: The Brigham and Women's Hospital, Whitehead Institute for Biomedical ResearchInventors: Tan A. Ince, Robert A. Weinberg
-
Patent number: 8372644Abstract: A method for growing adult cells includes harvesting a tissue sample from a subject and breaking the tissue sample into fragments. The fragments are placed into a culture vessel, and at least some of the fragments are induced to adhere to the culture vessel. The fragments are supplied with nutrients so that adult cells contained therein divide and grow.Type: GrantFiled: February 6, 2007Date of Patent: February 12, 2013Assignee: Transplantation LimitedInventors: Patrick J. Casey, Richard Fry, Kerri Fry
-
Patent number: 8318492Abstract: The present invention relates in one aspect to a method for determining the cell culture history of a cell unit labelled with more than one type of tag comprising the steps of: (a) measuring one or more parameters of each tag that is used to label the cell unit; (b) identifying each tag in the cell unit; and (c) correlating the identity of each tag to the identity of the cell unit and/or the specific cell culture conditions to which the cell unit has been exposed.Type: GrantFiled: February 25, 2008Date of Patent: November 27, 2012Assignee: Plasticell LimitedInventors: Yen Choo, Fraser Hornby, John Girdlestone
-
Publication number: 20120270319Abstract: The invention is directed to substantially purified amnion-derived cell populations, compositions comprising the substantially purified amnion-derived cell populations, and to methods of creating such substantially purified amnion-derived cell populations, as well as methods of use. The invention is further directed to antibodies, in particular, monoclonal antibodies, that bind to amnion-derived cells or, alternatively, to one or more amnion-derived cell surface protein markers. The invention is further directed to methods for producing the antibodies, methods for using the antibodies, and kits comprising the antibodies.Type: ApplicationFiled: October 6, 2011Publication date: October 25, 2012Inventors: Diana L. Clarke, Charlotte A. Smith, Richard A. Banas, Vivienne S. Marshall
-
Patent number: 8236299Abstract: A method of treating neurodegenerative conditions is provided. Neural stem cells may be implanted at and/or remote from a region of neuron degeneration. The methods can include isolating neural stem cells from regions where specific types of neurons corresponding to the neurons to be replaced are generated. The methods can include isolating neural stem cells secreting growth factors affecting the growth and/or regeneration of specific types of neuron. In this invention, we disclose a method of treating such disorders, including several neurodegenerative disorders arising from the lack of cells that produce particular neurotransmitters in neural circuitry by transplanting exogenously cultured and expanded neural progenitors which, upon transplantation into a neural tissue, differentiate into neurons capable of integrating and producing neurotransmitters in sufficient quantities and in a sufficient manner to overcome the symptoms associated with the neurodegeneration.Type: GrantFiled: February 22, 2010Date of Patent: August 7, 2012Assignee: NeuralStem, Inc.Inventors: Karl K. Johe, Thomas G. Hazel
-
Patent number: 8211698Abstract: The invention provides neuronal progenitor cells, populations and cultures of cells, cell compositions and methods of producing neuronal progenitor cells. Neuronal progenitor cells can be prepared from embryonic stem cells, such as human embryonic stem cells.Type: GrantFiled: August 4, 2008Date of Patent: July 3, 2012Assignee: California Stem Cells, Inc.Inventor: Aleksandra Jovanovic Poole
-
Publication number: 20120148536Abstract: A method for the isolation, storage and retrieval of mature retinal cells is disclosed. The Method is applicable to adult mammalian cone cells, and more particularly human cone cells, and to healthy as well as pathological or otherwise altered cone cells. A kit for the isolation, storage and retrieval of mature retinal cells is also described.Type: ApplicationFiled: December 14, 2010Publication date: June 14, 2012Applicant: MOREHOUSE SCHOOL OF MEDICINEInventors: Peter R. MACLEISH, Xiaoming Chen
-
Publication number: 20120077268Abstract: The present invention relates to a process for culturing animal cells, e.g., human, diploid anchorage-dependent cells, in the absence of exogenous components of primary animal origin. In particular, the invention provides cell culture media substantially free of exogenous components of primary and secondary animal origin which comprises at least one, more preferably several, exogenous animal-free growth factors. The present invention also relates to a process for cultivating animal cells using a protease of non-animal origin for passaging cells.Type: ApplicationFiled: October 10, 2011Publication date: March 29, 2012Applicant: GlaxoSmithKline Biologicals, s.a.Inventors: Brigitte Ghislaine Louise Aerts, Yves Jules Maurice Ghislain, Marie-Monique Jane Gonze, Isabelle Solange Lucie Knott, Carine Maggetto
-
Publication number: 20120003691Abstract: The present invention provides methods of isolation and purification of Streptomyces griseus trypsin (SGT) from PRONASE protease mixture in a single affinity chromatography step and uses of the purified SGT.Type: ApplicationFiled: December 28, 2009Publication date: January 5, 2012Applicant: Baxter Healthcare S.A.Inventors: Artur Mitterer, Christa Tauer, Manfred Reiter, Wolfgang Mundt
-
Patent number: 7964402Abstract: We used Accutase™, a commercially available cell detachment solution, for single cell propagation of pluripotent hESCs. Unlike trypsin dissociation, Accutase treatment does not significantly affect the plating efficiency of hESC dissociation into single cells. Cultures dissociated with Accutase to single cells at each passage maintain a higher proportion of pluripotent cells as compared to collagenase-passaged hESCs. Accutase-treated hESCs can be grown to a high density as monolayers, and yet retain their pluripotency.Type: GrantFiled: May 24, 2007Date of Patent: June 21, 2011Assignee: Sanford-Burnham Medical Research InstituteInventors: Alexey Terskikh, Ruchi Bajpai
-
Patent number: 7955851Abstract: The present invention is of methods of establishing and propagating human embryonic stem cell lines using feeder cells-free, xeno-free culture systems and stem cells which are capable of being maintained in an undifferentiated, pluripotent and proliferative state in culture which is free of xeno contaminants and feeder cells.Type: GrantFiled: September 21, 2009Date of Patent: June 7, 2011Assignee: Technion Research & Development Foundation Ltd.Inventors: Michal Amit, Joseph Itskovitz-Eldor
-
Publication number: 20110104735Abstract: The present invention discloses novel methods and omental, myocardial, liver, lung, renal, peritoneal, intestinal and pancreatic mesothelial cells which are useful for a number of procedures including drug discovery, co-culturing, cell therapy and bioassay. The invention provides a method for isolating these cells that improves upon the methods previously used and provides cells isolated in quantity. The present invention provides a list of secreted proteins from omentum mesothelial cells that can be utilized in the described cell based assays.Type: ApplicationFiled: November 1, 2010Publication date: May 5, 2011Inventors: BENJAMIN MARCUS BUEHRER, RICHARD BENTLEY CHEATHAM, JAMES BRADFORD NICOLL, PETER EARL PIERACCINI
-
Publication number: 20110070648Abstract: The present invention relates to a method for cell expansion. More closely, it relates to a method for expansion of cells, such as mesenchymal stem cells, on microcarriers in a plastic bag bioreactor. The invention enables expansion to therapeutic amounts of stem cells. The method comprises the following steps: a) addition of cells in cell culture medium and microcarriers to a plastic bag container; b) allowing the cells to adhere to the microcarriers while the container is kept substantially still; c) addition of further cell culture medium once the cells have adhered; d) culturing the cells under gentle and constant agitation; e) increase the surface area for continued culturing; and f) final harvesting of cells by an active detachment and separation step.Type: ApplicationFiled: May 11, 2009Publication date: March 24, 2011Applicant: GE HEALTHCARE BIO-SCIENCES ABInventors: Cecilia Anneren, Linnea Pauler
-
Patent number: 7829336Abstract: The present invention relates to methods for isolating infrequently-dividing, slow-cycling cells, a feature which is typical of stem cells in their niche. The methods of the present invention are advantageously used as classical stem cells can be isolated. Further provided are methods for generating clonal populations and inhibiting the differentiation of these cells. In addition markers for distinguishing these cells from progenitor cells are also disclosed.Type: GrantFiled: November 12, 2004Date of Patent: November 9, 2010Assignee: The Rockefeller UniversityInventors: Elaine Fuchs, Tudorita Tumbar, Cedrick Blanpain, William E. Lowry
-
Patent number: 7824869Abstract: The invention is directed to a method for altering the ion conductivity of a membrane. The method comprises inserting a biological photoreceptor into the membrane. The biological photoreceptor is configured to act as a light-controlled ion channel. The photoreceptor used comprises an apoprotein and a light-sensitive polyene covalently bound to the apoprotein, wherein the polyene interacts with the apoprotein and functions as a light-sensitive gate.Type: GrantFiled: April 11, 2003Date of Patent: November 2, 2010Assignee: Max-Planck-Gesellschaft zur Foerderung der Wissenschaften E.V.Inventors: Peter Hegemann, Georg Nagel, Ernst Bamberg
-
Patent number: 7547546Abstract: Human progenitor cells are extracted from perivascular tissue of human umbilical cord. The progenitor cell population proliferates rapidly, and harbours osteogenic progenitor cells and MHC?/? progenitor cells, and is useful to grow and repair human tissues including bone.Type: GrantFiled: October 8, 2004Date of Patent: June 16, 2009Assignee: Tissue Regeneration Therapeutics Inc.Inventors: John E. Davies, Dolores Baksh, Rahul Sarugaser, Morris Hosseini, Antony D. S. Lickorish
-
Publication number: 20090053810Abstract: The invention relates to a method of introducing a substance into a multi-layered cell factory. A substance is poured into a substance transferring device e.g. a funnel and a tube connected to the cell factory, which directly transfers the substance into the cell factory arranged with its layers extending substantially vertically. The invention also relates to a cell-cultivation system.Type: ApplicationFiled: April 10, 2006Publication date: February 26, 2009Applicant: ASTRAZENECA ABInventors: Laura Sander, Annika Sundberg
-
Publication number: 20080267921Abstract: Human cardiac stem cells can be isolated from endomyocardial biopsies. Such cells mediate cardiac regeneration and improve heart function in a mouse infarct model. The cells can be used for autologous, allogeneic, syngeneic, or xenogeneic therapeutic applications in patients. The stem cells can be genetically modified to enhance their therapeutic activity.Type: ApplicationFiled: November 8, 2005Publication date: October 30, 2008Applicant: Johns Hopkins UniversityInventors: Eduardo Marban, Maria Roselle Abraham, Rachel R. Smith
-
Patent number: 7354733Abstract: We disclose methods of sorting or separating mixtures of living cells (e.g., eukaryotic, prokaryotic, mammalian, pathogenic, bacterial, viral, etc.). We perform our methods by activating cell-selective photophoric labels, which photosensitize and chemically reduce a photosensitive metal compound to form metal grains, particles or crystals. The metal adheres to the cells and forms the basis for sorting or separating different cell types. Photophoric labels may include chemiluminescent agents such as peroxidase enzymes activated with peroxidase substrates capable of luminescence. Photosensitive metal compounds may be present in a light-sensitive matrix or emulsion containing photosensitizable metal compounds, which form metal grains, particles or crystals upon exposure to a developer solution. Developer solutions are formulated to substantially allow living cells to remain viable after exposure to the developing solution.Type: GrantFiled: March 26, 2002Date of Patent: April 8, 2008Assignee: Cellect Technologies Corp.Inventors: Shmuel Bukshpan, Gleb Zilberstein
-
Patent number: 7166477Abstract: A method of preparing a sample of muscle tissue and of assaying the prepared sample to determine the presence of prions in the sample is disclosed. The muscle tissue is homogenized and mixed with a complexing agent which forms a complex with a higher specific gravity than PrPSc, the complexing agent or other components of the homogenate. Gravity is then used (e.g. ultra centrifugation) to concentrate the complex and the concentrate is assayed to detect prions. The muscle tissue is preferably extracted from a muscle or group of muscles such as hind limb muscle which have a higher or more preferably the highest concentration of prions as compared to other muscle in the mammal.Type: GrantFiled: August 2, 2002Date of Patent: January 23, 2007Assignee: The Regents of the University of CaliforniaInventors: Stanley B. Prusiner, Patrick Bosque
-
Patent number: 7109028Abstract: This invention relates to methods of isolating hepatoblasts utilizing panning techniques and fluorescence activated cell sorting. This invention further relates to isolated hepatoblasts and to a method of treating liver dysfunction as well as to methods of forming artificial livers.Type: GrantFiled: June 5, 2001Date of Patent: September 19, 2006Assignee: Albert Einstein College of Medicine of Yeshiva UniversityInventors: Lola M. Reid, Samuel H. Sigal, Shlomo Brill, Patricia A. Holst
-
Patent number: 7049141Abstract: The invention provides a method for using collagenase to dissociate neural stem cells in neural stem cell cultures. The collagenase treatment results in an increased cell viability and an increased number of proliferated neural stem cells over time.Type: GrantFiled: February 25, 2000Date of Patent: May 23, 2006Assignee: StemCells California, Inc.Inventor: Nobuko Uchida
-
Patent number: 7045349Abstract: Advanced Islet Separation Technology incorporates an automated method, automated control methodology, process control interface, and automated apparatus to separate (isolate) and process pancreatic islets in a tissue suspension in physiologic process solution, utilizing microprocessor controllers and computer control and software programming to interface and control the process temperature, process flowrate, percent hydrogen concentration, dissolved oxygen concentration, endotoxin concentration, dissolved nitric oxide concentration, nitric oxide synthase concentration, proteolytic enzyme activity, and pressure of the islet containing physiologic process solution, including real-time process data acquisition and recording of the process variables.Type: GrantFiled: January 23, 2002Date of Patent: May 16, 2006Inventors: Daniel J. Benedict, Lorna S. Mosse
-
Patent number: 6900051Abstract: The present invention relates to a process for obtaining mammalian insulin secreting cells in vitro, characterized in that it contains the following steps: a) preparation of the mammalian pancreatic tissues by removal of a pancreas, b) dissociation of the pancreatic tissues obtained in step (a) into isolated pancreatic cells, c) possibly the elimination of the endocrine cells from the pancreatic cells isolated in step (b), d) induction of dedifferentiation of the cells isolated in step (b) into ductal precursor cells, e) induction of redifferentiation of the ductal precursor cells obtained in step (d) into insulin secreting cells. It also concerns the use of the insulin secreting cells thus obtained for the preparation of a pharmaceutical composition which can be used for the treatment of pancreatic pathologies and particularly diabetes.Type: GrantFiled: September 21, 2001Date of Patent: May 31, 2005Assignee: Centre Hospitalier Regional Universitaire De LilleInventors: Julie Kerr-Conte, Françoise Pattou
-
Patent number: 6869771Abstract: A method for distributing an equal volume of attached confluent living cells in each well of a multi-well plate used in a bioassay, comprising the following steps: (a) growing attached living cells on a medium until the cells are confluent; (b) treating the attached confluent living cells with an enzyme solution, whereby the solution and the attached confluent living cells make a cell suspension; (c) filtering the cell suspension with a filter; (d) collecting a cell suspension filtrate containing uniformly distributed attached confluent living cells therein; and (e) distributing an equal volume of the cell suspension filtrate into wells of a plate whereby each well has an equal volume of cells for use in any bioassay.Type: GrantFiled: August 19, 2002Date of Patent: March 22, 2005Assignee: Access Business Group International LLCInventor: Yong Qian
-
Patent number: 6833270Abstract: An apparatus and method for extracting cells from organs in which a digestion chamber includes at least one inlet and at least one outlet, and a separator for retaining the organ and permitting the cells and the physiologically compatible medium to exit the outlet. The digestion chamber can also includes at least one agitation member having an interior with at least one void. An agitation member for extracting cells from organs is also disclosed.Type: GrantFiled: November 27, 2001Date of Patent: December 21, 2004Assignees: Biorep Technologies, Inc., The University of MiamiInventors: Ramon E. Poo, Camillo Ricordi
-
Patent number: 6825027Abstract: The present invention provides methods of purification of Hepatitis A Virus from the supernatant of an infected cell culture and production of a preparation of purified HAV antigen. The present invention is also directed to an HAV vaccine composition comprising a preparation consisting of purified mature HAV particles in an amount sufficient to induce a protective immune response in a mammal.Type: GrantFiled: December 10, 2001Date of Patent: November 30, 2004Assignee: Baxter Healthcare S.A.Inventors: Christa Tauer, Heidi Meyer, Artur Mitterer, Noel Barrett
-
Publication number: 20040180434Abstract: The subject invention pertains to compositions and methods for culturing nerve tissue in vitro and nerve grafts produced using such methods. The compositions and methods of the subject invention can be employed to restore the continuity of nerve interrupted by disease, traumatic events or surgical procedures. The invention also concerns methods for promoting repair of damaged nerve tissue using the present compositions and nerve tissue treated according to such methods.Type: ApplicationFiled: March 29, 2004Publication date: September 16, 2004Inventor: David F. Muir
-
Publication number: 20040137618Abstract: The present invention relates to decellularized vascular prostheses that are resistant to thrombus occlusion and have a low level of immunogenicity. The vascular prostheses are denuded of cells, and coated with an anti-thrombogenic agent and a growth factor that promotes recellularization and further reduces the immunogenicity. The prostheses have high mechanical strength, resist aneurysm rupture, and allow for secure surgical sutures while maintaining structural integrity. The present invention provides vascular prostheses that are blood vessels, valves or portions of vessels containing valves. The present invention is also useful for coating synthetic vascular stents.Type: ApplicationFiled: November 6, 2003Publication date: July 15, 2004Inventors: Changyi Chen, Alan B. Lumsden
-
Publication number: 20040010306Abstract: The present invention relates to medical devices that are to be implanted or inserted into the body of a patient for the purpose of removing undesired body tissues. In one embodiment of the invention the medical device comprises a body tissue removal agent for removing undesired body tissue simultaneously with or prior to treatment of body tissue that is in proximity to the undesired body tissue with a biologically active material. Such biologically active material may facilitate regeneration of the body tissue that was removed or may prevent the recurrence of the undesired body tissue.Type: ApplicationFiled: July 12, 2002Publication date: January 15, 2004Inventors: Toby Freyman, Wendy Naimark
-
Patent number: 6585969Abstract: Cultures of keratinocyte cells are provided which are free from nonautologous fibroblasts and organ extracts, and which have a high speed of cell amplification for a minimum seeding density. The cultures can be cryopreserved in a buffered isotonic medium containing serum and a cryoprotectant. The cultures are produced by a process that does not involve the use of a feeder layer and organ extracts. A culture medium which can be used contains Medium 199, serum, epidermal growth factor, cholera toxin and/or hydrocortisone, and optionally insulin. A substance for wound healing and for cosmetic applications is derived from cultured human keratinocytes. A non-viable total keratinocyte lysate for use in promoting wound healing is produced by growing keratinocyte cells on a support, detaching the cells from the support, and lysing the detached cells to obtain the lysate which may be frozen and lyophilized.Type: GrantFiled: February 1, 1999Date of Patent: July 1, 2003Assignee: N. V. Innogenetics S.A.Inventor: Hans Van Bossuyt
-
Patent number: 6489164Abstract: A method for isolating specific viable cell types from surrounding organ tissue is provided. The method entails the use of sonication in conjunction with tissue dissociating agents to free the cells of interest. A specific application of the method is the isolation of the insulin producing tissue of the pancreas, the islets of Langerhans. The method results in a high yield of islets that maintain a high level of viability.Type: GrantFiled: August 10, 1998Date of Patent: December 3, 2002Assignee: Novocell, Inc.Inventors: Brad Gray, Monty Kahn Baird, Francis Lamberti
-
Publication number: 20020127719Abstract: The invention provides an article of manufacture comprising a substantially non-immunogenic heart valve xenograft for implantation into humans. The invention further provides methods for preparing a heart valve xenograft by removing at least a portion of a soft tissue from a non-human animal to provide a xenograft; washing the xenograft in saline and alcohol; subjecting the xenograft to cellular disruption treatment; treating the xenograft with crosslinking agents, and digesting the xenograft with a proteoglycan-depleting factor and/or glycosidase. The invention also provides an article of manufacture produced by the above-identified method of the invention. The invention further provides a heart valve xenograft for implantation into a human including a portion of a heart valve from a non-human animal, wherein the portion has extracellular components and substantially only dead cells. The extracellular components have reduced proteoglycan molecules.Type: ApplicationFiled: May 6, 2002Publication date: September 12, 2002Inventor: Kevin R. Stone
-
Patent number: 6383805Abstract: A method and a medium for culturing epithelial cells of both normal and malignant origin is provided. The method entails physically disaggregating tissue samples, placing the resulting fragments onto a surface comprised of basement membrane matrix components, and culturing the tissue in a medium containing preselected fetal and newborn calf sera and rat sera. Both primary explant cell cultures and cell lines, which are long-lived and particularly suitable for further study, are produced. The cultured primary explant cells undergo differentiation to form complex structures resembling those seen in vivo.Type: GrantFiled: April 11, 2000Date of Patent: May 7, 2002Assignee: University of PittsburghInventor: Jean J. Latimer
-
Patent number: 6365405Abstract: This invention concerns compositions of chondrocytic cells, notably human ones, and the methods for preparing and using them. More specifically, the invention describes the production of autologous human chondrocyte suspensions, employing recombinant enzymes and/or media that are compatible with pharmaceutical use. The invention also describes methods and compositions for freezing chondrocytes, notably in the absence of DMSO. The chondrocytes which are produced can be used in vivo to restore affected cartilaginous structures, such as in post-traumatic cartilaginous defects or dissecting osteochondrite of the knee or, more generally, for treating and repairing clinically significant defects in cartilage, notably in joint cartilage.Type: GrantFiled: September 15, 2000Date of Patent: April 2, 2002Assignee: Universite Pierre et Marie Curie (Paris IV)Inventors: Jean-Loup Salzmann, Andrès Crespo, David Klatzmann, Norbert Passuti
-
Patent number: 6242252Abstract: This invention relates to methods of isolating hepatic progenitors utilizing panning techniques and fluorescence activated cell sorting. This invention further relates to isolated hepatic progenitors and to a method of treating liver dysfunction as well as to methods of forming artificial livers.Type: GrantFiled: September 16, 1998Date of Patent: June 5, 2001Assignee: Albert Einstein College of Medicine of Yeshiva UniversityInventors: Lola M. Reid, Samuel H. Sigal, Shlomo Brill, Patricia A. Holst